Cetrelimab
- Product Name
- Cetrelimab
- CAS No.
- 2050478-92-5
- Chemical Name
- Cetrelimab
- Synonyms
- Cetrelimab;Cetrelimab (anti-PDCD1);Research Grade Cetrelimab;Research Grade Cetrelimab(DHH02204)
- CBNumber
- CB28081085
- Formula Weight
- 0
- MOL File
- Mol file
Cetrelimab Property
- form
- Liquid
- color
- Colorless to light yellow
N-Bromosuccinimide Price
- Product number
- HY-P99499
- Product name
- Cetrelimab
- Purity
- 99.0%
- Packaging
- 1mg
- Price
- $285
- Updated
- 2026/05/26
- Product number
- HY-P99499
- Product name
- Cetrelimab
- Purity
- 99.0%
- Packaging
- 5mg
- Price
- $741
- Updated
- 2026/05/26
- Product number
- HY-P99499
- Product name
- Cetrelimab
- Purity
- 99.0%
- Packaging
- 10mg
- Price
- $1188
- Updated
- 2026/05/26
- Product number
- A421
- Product name
- Cetrelimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
- Purity
- >98%
- Packaging
- 1mg
- Price
- $450
- Updated
- 2026/05/24
- Product number
- A421
- Product name
- Cetrelimab Biosimilar(Anti-PDCD1 / PD-1 / CD279 Reference Antibody)
- Purity
- >98%
- Packaging
- 5mg
- Price
- $750
- Updated
- 2026/05/24
Cetrelimab Chemical Properties,Usage,Production
Uses
Cetrelimab (JNJ 63723283; JNJ 3283) is a human IgG4κ mAb targeting PD-1. Cetrelimab binds PD-1 (Kd=1.72 nM, HEK293) to block the interaction of PD-1 with PD-L1 and PD-L2 (IC50s=111.7 ng/mL and 138.6 ng/mL, respectively). Cetrelimab stimulates peripheral T cells, increases IFN-γ, IL-2, TNF-α level and inhibits tumor growth in vivo[1].
in vivo
Cetrelimab (10 mg/kg; i.p.; single dose) has antitumor efficacy, and decreases tumor volume in PD-1 knock-in (hPD-1KI) mice with MC38 tumor[1].
Cetrelimab (10 mg/kg; i.p.; once every 5 days for 30 d) results significant increases in peripheral blood CD8+ T cells in patient-derived xenograft (PDX) lung model in mice[1].
Cetrelimab (10-100 mg/kg; i.v.; once weekly for 5 weeks) has well tolerance in cynomolgus model[1].
Cetrelimab (0.1-10 mg/kg; i.v.; single dose, monitored for 57 d) shows an nonlinear pharmacokinetics (PK) in cynomolgus, possibly attributable to target-mediated drug deposition (TMDD)[1].
| Animal Model: | hPD-1KI model with mouse PD-1 ECD replaced by the human PD-1 ECD[1] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection; single dose at day 7 after tumor implantation |
| Result: | hPD-1KI mice develop normally and have no immune abnormalities. Significantly lowered tumor volume at Day 21. |
| Animal Model: | Patient-derived xenograft (PDX) LG1306 lung model in mice[1] |
| Dosage: | 10 mg/kg |
| Administration: | Intraperitoneal injection; every 5 days for 6 cycles |
| Result: | Significantly reduced patient-derived tumor volume by 32%. |
| Animal Model: | Good Laboratory Practice (GLP) toxicity study in cynomolgus[1] |
| Dosage: | 0, 10, 30, or 100 mg/kg |
| Administration: | Intravenous injection; once weekly for 5 weeks |
| Result: | Showed well tolerance in cynomolgus. |
References
[1] DeAngelis N, et al. Discovery and pharmacological characterization of cetrelimab (JNJ-63723283), an anti-programmed cell death protein-1 (PD-1) antibody, in human cancer models. Cancer Chemother Pharmacol. 2022 Apr;89(4):515-527. DOI:10.1007/s00280-022-04415-5
Cetrelimab Preparation Products And Raw materials
Raw materials
Preparation Products
Cetrelimab Suppliers
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 89686
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 7999
- Advantage
- 62
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ：422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 4008200310 15002144251
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24955
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9865
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 7081
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11972
- Advantage
- 58
- Tel
- 027-027-16602739303 16602739303
- 673003916@qq.com
- Country
- China
- ProdList
- 4565
- Advantage
- 58
- Tel
- 6206333 13167063860
- anhua.mao@aladdin-e.com
- Country
- China
- ProdList
- 49998
- Advantage
- 58